Alpha 2.0
Login Register
» Authors » Robert Paridaens

Robert Paridaens

Explore the profile of Robert Paridaens including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 93
Citations 4817
Followers 0
Related Specialties
Oncology
General Medicine
Genetics
Top 10 Co-Authors
Patrick Neven
Hans Wildiers
Marie-Rose Christiaens
Ann Smeets
Ignace Vergote
Diether Lambrechts
Frederic Amant
Ben Van Calster
Philippe Moerman
Cornelis J H van de Velde
Published In
J Clin Oncol
Breast Cancer Res Treat
Curr Opin Oncol
Support Care Cancer
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials
Noordhoek I, Blok E, Meershoek-Klein Kranenbarg E, Putter H, Duijm-de Carpentier M, Rutgers E, et al.
J Clin Oncol . 2020 Jul; 38(28):3273-3281. PMID: 32706636
Purpose: Most distant recurrences (DRs) in women with hormone receptor-positive breast cancer occur after 5 years from diagnosis. The Clinical Treatment Score post-5 years (CTS5) estimates DRs after 5 years...
2.
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Dieras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, et al.
Breast Cancer Res Treat . 2019 Jun; 177(2):383-393. PMID: 31172407
Purpose: Metastatic triple-negative breast cancer (TNBC) is a phenotypic breast cancer subgroup with a very poor prognosis, despite standard treatments. Combined twice-weekly iniparib and gemcitabine/carboplatin (GC+tw-iniparib) showed benefit over gemcitabine/carboplatin...
3.
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, et al.
Oncologist . 2018 Sep; 24(2):165-171. PMID: 30171067
Background: In estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER-2) negative breast cancers, the progesterone receptor (PR) is an independent prognostic marker. Little is known about the prognostic...
4.
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, et al.
Clin Cancer Res . 2018 Feb; 24(10):2312-2318. PMID: 29459457
Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochrome P450 (CYP) 2D6 enzyme. We prospectively investigated tamoxifen efficacy by serum endoxifen levels and the...
5.
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
Derks M, Blok E, Seynaeve C, Nortier J, Meershoek-Klein Kranenbarg E, Liefers G, et al.
Lancet Oncol . 2017 Jul; 18(9):1211-1220. PMID: 28732650
Background: After 5 years of median follow-up, the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial reported no difference in disease-free survival between exemestane monotherapy and a sequential scheme of tamoxifen followed...
6.
Long-Term Follow-Up of the Intergroup Exemestane Study
Morden J, Alvarez I, Bertelli G, Coates A, Coleman R, Fallowfield L, et al.
J Clin Oncol . 2017 May; 35(22):2507-2514. PMID: 28467729
Purpose The Intergroup Exemestane Study, an investigator-led study of 4,724 postmenopausal patients with early breast cancer (clinical trial information: ISRCTN11883920), has previously demonstrated that a switch from adjuvant endocrine therapy...
7.
Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm
Jongen L, Paridaens R, Floris G, Wildiers H, Neven P
Breast Cancer Res Treat . 2016 Feb; 155(3):603-7. PMID: 26868122
We report on a postmenopausal patient with a secondary metastatic apocrine breast cancer successfully treated with low-dose hydrocortisone only following several lines of chemotherapy. The tumor cells in the primary...
8.
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients
Vulsteke C, Pfeil A, Maggen C, Schwenkglenks M, Pettengell R, Szucs T, et al.
Breast Cancer Res Treat . 2015 May; 152(1):67-76. PMID: 26017071
Anthracycline-induced cardiotoxicity (ACT) is a well-known serious adverse drug reaction leading to substantial morbidity. The purpose of this study was to assess ACT occurrence and clinical and genetic risk factors...
9.
MicroRNA related polymorphisms and breast cancer risk
Khan S, Greco D, Michailidou K, Milne R, Muranen T, Heikkinen T, et al.
PLoS One . 2014 Nov; 9(11):e109973. PMID: 25390939
Genetic variations, such as single nucleotide polymorphisms (SNPs) in microRNAs (miRNA) or in the miRNA binding sites may affect the miRNA dependent gene expression regulation, which has been implicated in...
10.
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens
Lintermans A, Vanderschueren D, Verhaeghe J, Van Asten K, Jans I, Van Herck E, et al.
Eur J Cancer . 2014 Oct; 50(17):2925-31. PMID: 25304297
Background: Aromatase inhibitors (AIs) frequently induce or enhance musculoskeletal problems (AI-induced musculoskeletal syndrome (AIMSS)) which sometimes are debilitating. Apart from low oestrogen levels, underlying mechanisms are unknown and likely multiple....